• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon to Present at 2025 Baird Global Healthcare Conference

    8/26/25 8:00:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email

    Alcon (SIX/NYSE:ALC) CEO David Endicott will present at the 2025 Baird Global Healthcare Conference on Tuesday, September 9, 2025, at 9:05 a.m. ET.

    A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250825890284/en/

    Investor Relations

    Daniel Cravens

    Allen Trang

    + 41 589 112 110 (Geneva)

    + 1 817 615 2789 (Fort Worth)

    [email protected]

    Media Relations

    Steven Smith

    + 41 589 112 111 (Geneva)

    + 1 817 551 8057 (Fort Worth)

    [email protected]

    Get the next $ALC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    8/21/2025Overweight → Neutral
    Analyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    3/25/2025Neutral → Buy
    BofA Securities
    1/24/2025$108.00 → $106.00Buy
    Needham
    1/10/2025Neutral → Buy
    Redburn Atlantic
    12/17/2024$103.00 → $108.00Buy
    Needham
    More analyst ratings

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon to Present at 2025 Baird Global Healthcare Conference

    Alcon (SIX/NYSE:ALC) CEO David Endicott will present at the 2025 Baird Global Healthcare Conference on Tuesday, September 9, 2025, at 9:05 a.m. ET. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than

    8/26/25 8:00:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon downgraded by Analyst

    Analyst downgraded Alcon from Overweight to Neutral

    8/21/25 8:12:09 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Deutsche Bank

    Deutsche Bank downgraded Alcon from Buy to Hold

    5/20/25 8:02:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    BTIG Research reiterated coverage on Alcon with a new price target

    BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

    5/14/25 11:06:26 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    SEC Filings

    View All

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    8/19/25 4:31:11 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form DEFM14A filed by Alcon Inc.

    DEFM14A - ALCON INC (0001167379) (Filer)

    8/5/25 7:21:07 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    8/5/25 7:18:06 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Financials

    Live finance-specific insights

    View All

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

    First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

    5/13/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/23 1:35:38 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/22 5:01:03 PM ET
    $ALC
    Ophthalmic Goods
    Health Care